GoAI
Get started
Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc.

NVCT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$23.56

+$0.21 · +0.90%

Aug 21, 4:00 PM ET

NVCT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

29

Expensive

Momentum

71

Gaining

Sentiment

74

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Ron Bentsur
Listed since
Feb 4, 2022
Employees
16

Market position

Day range

Current $23.56

52-week range

Current $23.56

Open
$23.605
Previous close
$23.35
Volume
196.98K
0.8× average
Average volume
247.02K
Average daily volume
Market cap
625.2M USD
Beta
-0.26
Market reference 1
50-day average
$19.2901
+22.14% above average
200-day average
$11.0912
+112.42% above average

Financials

Financial statements

Income trends

Operating income

−27.57M USD-38.93%

Net income

−26.44M USD-39.17%
Income trends across reported periods−11.42M USD−17.3M USD−23.17M USD−29.04M USDOperating income, FY2021: −12.89M USDOperating income, FY2022: −19.23M USDOperating income, FY2023: −22.9M USDOperating income, FY2024: −19.85M USDOperating income, FY2025: −27.57M USDNet income, FY2021: −12.89M USDNet income, FY2022: −19.09M USDNet income, FY2023: −22.26M USDNet income, FY2024: −19M USDNet income, FY2025: −26.44M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −12.89M USD. Operating income FY2022 −19.23M USD. Operating income FY2023 −22.9M USD. Operating income FY2024 −19.85M USD. Operating income FY2025 −27.57M USD. Net income FY2021 −12.89M USD. Net income FY2022 −19.09M USD. Net income FY2023 −22.26M USD. Net income FY2024 −19M USD. Net income FY2025 −26.44M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development18.15M USD12.92M USD15.38M USD13.23M USD9.55M USD
Selling, general, and administrative9.42M USD6.93M USD7.52M USD6.01M USD3.35M USD
Operating expenses27.57M USD19.85M USD22.9M USD19.23M USD12.89M USD
Interest income1.13M USD847K USD637K USD149K USD4K USD
Operating income−27.57M USD−19.85M USD−22.9M USD−19.23M USD−12.89M USD
Net income−26.44M USD−19M USD−22.26M USD−19.09M USD−12.89M USD

Company facts updated Aug 24, 2026.

NVCT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NVCT

research.disclaimer